Alto Neuroscience Inc (ANRO) Stock Price, Quote & News

Company Profile

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule ph...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 200 0412

Website: www.altoneuroscience.com

Address:

650 Castro Street, Suite 450, Mountain View, United States

anachartanalyst Aug. 13 at 11:01 AM

$ANRO https://anachart.com/wp-content/uploads/2026/08/1786618882_soc-img.jpg

0 · Reply

fda_tracker Aug. 5 at 3:04 PM

$ANRO Phase 2 trial w/est Aug completion date NCT06656416: https://www.clinicaltrials.gov/study/NCT06656416 Trial Tracker: https://www.fdatracker.com/trial-tracker/

0 · Reply

BioTuesdays Aug. 4 at 1:03 PM

$ANRO is aiming to redefine the way neuropsychiatric conditions are treated through a biology-driven pipeline designed to deliver more effective treatment options. Drawing on expertise in central nervous system (CNS) drug development and commercialization, the company is seeking to move psychiatry beyond its traditional trial-and-error approach. https://biotuesdays.com/2026/08/04/alto-disrupting-the-trial-and-error-approach-to-treating-neuropsychiatric-disorders/

0 · Reply

Dogster304 Jul. 31 at 10:38 AM

$ANRO been with this beauty since it was $5 a share

0 · Reply

TripleWitch Jul. 14 at 1:44 AM

$ANRO $PSNL You must mean the one that did the after hours equity offering, no? 🤷‍♂️

0 · Reply

RunnerSignals Jul. 13 at 7:53 PM

red to green $PSNL and $ANRO flipped the script into the close, but one reversal had the cleaner volume signature. traders may be watching the wrong winner

0 · Reply

focafoca99 Jul. 13 at 12:12 PM

$ANRO estimated its cash, cash equivalents and restricted cash at about $244.2 million as of June 30, 2026.

0 · Reply

FaithFilledTrader Jul. 13 at 11:44 AM

$ANRO news

0 · Reply

DiamondHandsJimbo Jul. 10 at 5:59 PM

$ANRO 😝🔥🚀

0 · Reply

DiamondHandsJimbo Jul. 10 at 4:43 PM

$ANRO show me some green LMAO… Entry at $26.14 🤞🚀

0 · Reply

Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Aug 12, 2026, 4:00 PM EDT - 23 hours ago

Alto Neuroscience Earnings release: Q2 2026

Aug 12, 2026, 4:00 PM EDT - 23 hours ago

Alto Neuroscience Quarterly report: Q2 2026

Aug 12, 2026, 7:00 AM EDT - 1 day ago

Alto Neuroscience Slides: Corporate presentation

2026-07-13T11:56:00.000Z - 4 weeks ago

Alto Neuroscience prices 3.78M shares at $26.48 in registered direct offering

Jul 13, 2026, 7:47 AM EDT - 4 weeks ago

Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock

Jun 16, 2026, 7:00 AM EDT - 2 months ago

Alto Neuroscience Transcript: 7th Annual HCW Neuro Perspectives Hybrid Conference

2026-06-15T12:16:21.000Z - 2 months ago

Alto Neuroscience highlights publication in Nature Medicine on Prime-Praxol

Jun 15, 2026, 8:03 AM EDT - 2 months ago

Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia

Jun 15, 2026, 7:00 AM EDT - 2 months ago

Alto Neuroscience Slides: Corporate presentation

Jun 3, 2026, 9:20 AM EDT - 2 months ago

Alto Neuroscience Transcript: Jefferies Global Healthcare Conference 2026

2026-05-28T12:48:57.000Z - 2 months ago

Alto Neuroscience appoints Miller to Board of Directors

May 28, 2026, 8:03 AM EDT - 2 months ago

Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors

2026-05-22T11:55:51.000Z - 2 months ago

Alto Neuroscience price target lowered to $33 from $35 at BofA

2026-05-18T11:43:06.000Z - 3 months ago

Alto Neuroscience price target lowered to $36 from $38 at Baird

May 15, 2026, 8:27 AM EDT - 3 months ago

Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award

2026-05-14T17:24:06.000Z - 3 months ago

Alto Neuroscience price target raised to $24 from $21 at Wedbush

May 13, 2026, 8:15 PM EDT - 3 months ago

Alto Neuroscience Transcript: Bank of America Global Healthcare Conference 2026

2026-05-13T13:07:17.000Z - 3 months ago

Alto Neuroscience reports Q1 EPS (80c) vs (56c) last year

May 13, 2026, 7:03 AM EDT - 3 months ago

Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights

May 13, 2026, 7:00 AM EDT - 3 months ago

Alto Neuroscience Earnings release: Q1 2026

May 13, 2026, 7:00 AM EDT - 3 months ago

Alto Neuroscience Quarterly report: Q1 2026

May 11, 2026, 6:00 PM EDT - 3 months ago

Alto Neuroscience Slides: Corporate presentation

May 11, 2026, 4:05 PM EDT - 3 months ago

Alto Neuroscience Announces Participation in Upcoming Investor Conferences

2026-05-04T20:26:52.000Z - 3 months ago

Alto Neuroscience initiated with a Buy at BofA

2026-05-04T12:31:04.000Z - 3 months ago

Alto Neuroscience presents Phase 2a data for ALTO-207 in MDD

May 4, 2026, 8:03 AM EDT - 3 months ago

Alto Neuroscience Presents Phase 2a Data for ALTO-207 in Major Depressive Disorder at SOBP Annual Meeting

2026-04-29T17:18:32.000Z - 3 months ago

Alto Neuroscience participates in a conference call with H. C. Wainwright

2026-04-21T13:15:23.000Z - 4 months ago

Alto Neuroscience initiates Phase 2b trial of ALTO-207 in TRD

Apr 21, 2026, 8:03 AM EDT - 4 months ago

Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression

2026-04-10T20:05:23.000Z - 4 months ago

Alto Neuroscience files to sell 6M shares of common stock for holders

Apr 10, 2026, 8:00 AM EDT - 4 months ago

Alto Neuroscience Registration statement: Registration filing

2026-04-02T16:29:46.000Z - 4 months ago

Alto Neuroscience’s ALTO-101 miss doesn’t impact thesis, says H.C. Wainwright

2026-04-02T13:05:12.000Z - 4 months ago

Alto Neuroscience price target lowered to $21 from $22 at Wedbush

2026-04-02T12:36:19.000Z - 4 months ago

Alto Neuroscience price target lowered to $38 from $41 at Baird

2026-04-02T12:34:41.000Z - 4 months ago

Alto Neuroscience price target lowered to $44 from $49 at JonesResearch

2026-04-01T20:36:14.000Z - 4 months ago

Alto Neuroscience announces ALTO-101 did not achieve statistical significance

Apr 1, 2026, 4:30 PM EDT - 4 months ago

Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements

Apr 1, 2026, 7:00 AM EDT - 4 months ago

Alto Neuroscience Slides: Corporate presentation

Mar 26, 2026, 8:00 AM EDT - 5 months ago

Alto Neuroscience Proxy statement: Proxy filing

Mar 26, 2026, 8:00 AM EDT - 5 months ago

Alto Neuroscience Proxy statement: Proxy filing

2026-03-18T11:15:42.000Z - 5 months ago

Alto Neuroscience price target raised to $41 from $22 at Baird

Mar 17, 2026, 12:00 PM EDT - 5 months ago

Alto Neuroscience Transcript: Stifel 2026 Virtual CNS Forum

Mar 16, 2026, 7:03 AM EDT - 5 months ago

Alto Neuroscience Announces $120 Million Private Placement Financing

Mar 16, 2026, 7:00 AM EDT - 5 months ago

Alto Neuroscience Earnings release: Q4 2025

Mar 16, 2026, 7:00 AM EDT - 5 months ago

Alto Neuroscience Annual report: Q4 2025

Mar 16, 2026, 7:00 AM EDT - 5 months ago

Alto Neuroscience Slides: Corporate presentation

Mar 16, 2026, 6:03 AM EDT - 5 months ago

Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights

Mar 13, 2026, 8:03 AM EDT - 5 months ago

Alto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum

Mar 3, 2026, 1:50 PM EST - 5 months ago

Alto Neuroscience Transcript: TD Cowen 46th Annual Health Care Conference

Feb 13, 2026, 8:04 AM EST - 6 months ago

Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia

Feb 3, 2026, 8:27 AM EST - 6 months ago

Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment

Jan 14, 2026, 7:27 AM EST - 7 months ago

Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression

Jan 13, 2026, 8:00 AM EST - 7 months ago

Alto Neuroscience Presents New Data at the 64th Annual Meeting of the American College of Neuropsychopharmacology

Jan 12, 2026, 7:00 AM EST - 7 months ago

Alto Neuroscience Slides: Corporate presentation

Dec 3, 2025, 4:05 PM EST - 9 months ago

Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08

Nov 28, 2025, 7:00 AM EST - 9 months ago

Alto Neuroscience Registration statement: Registration Filing

Nov 17, 2025, 10:30 AM EST - 9 months ago

Alto Neuroscience Transcript: Jefferies London Healthcare Conference 2025

Nov 12, 2025, 10:00 AM EST - 9 months ago

Alto Neuroscience Transcript: Stifel 2025 Healthcare Conference

Nov 12, 2025, 8:00 AM EST - 9 months ago

Alto Neuroscience Quarterly report: Q3 2025

Nov 12, 2025, 8:00 AM EST - 9 months ago

Alto Neuroscience Earnings release: Q3 2025

Nov 12, 2025, 7:57 AM EST - 9 months ago

Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Oct 28, 2025, 7:34 AM EDT - 10 months ago

Alto Neuroscience to Participate in Upcoming Investor Conferences

Oct 20, 2025, 7:03 AM EDT - 10 months ago

Alto Neuroscience Announces $50 Million Private Placement Financing

Oct 20, 2025, 7:01 AM EDT - 10 months ago

Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting

Oct 8, 2025, 9:56 AM EDT - 11 months ago

Johnson Fistel, PLLP Investigates Claims on Behalf of Alto Neuroscience, Inc. Long-Term Shareholders

Oct 3, 2025, 10:51 AM EDT - 11 months ago

Johnson Fistel, PLLP Investigates Claims on Behalf of Alto Neuroscience, Inc. Long-Term Shareholders

Oct 3, 2025, 7:34 AM EDT - 11 months ago

Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia

Sep 17, 2025, 1:20 PM EDT - 11 months ago

Alto Neuroscience Transcript: TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Sep 9, 2025, 2:00 PM EDT - 1 year ago

Alto Neuroscience Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 9, 2025, 7:09 AM EDT - 1 year ago

Alto Neuroscience Announces Robust Replication of EEG Biomarker to Objectively Identify Patients with Cognitive Impairment in Schizophrenia

Aug 18, 2025, 9:45 AM EDT - 1 year ago

Lawsuit DEADLINE: Investors who purchased over $100,000 worth of shares of Alto Neuroscience, Inc. (NYSE: ANRO) between Feb. and Oct. 2024 should contact the Shareholders Foundation

Aug 13, 2025, 4:10 PM EDT - 1 year ago

Alto Neuroscience Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 13, 2025, 4:00 PM EDT - 1 year ago

Alto Neuroscience Quarterly report: Q2 2025

Aug 13, 2025, 4:00 PM EDT - 1 year ago

Alto Neuroscience Earnings release: Q2 2025

Aug 13, 2025, 8:03 AM EDT - 1 year ago

Alto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.D., to Its Board of Directors

Aug 4, 2025, 2:46 PM EDT - 1 year ago

Alto Neuroscience, Inc. Investigated for Breaches of Fiduciary Duty - Contact the DJS Law Group to Discuss Your Rights – ANRO

anachartanalyst Aug. 13 at 11:01 AM

$ANRO https://anachart.com/wp-content/uploads/2026/08/1786618882_soc-img.jpg

0 · Reply

fda_tracker Aug. 5 at 3:04 PM

$ANRO Phase 2 trial w/est Aug completion date NCT06656416: https://www.clinicaltrials.gov/study/NCT06656416 Trial Tracker: https://www.fdatracker.com/trial-tracker/

0 · Reply

BioTuesdays Aug. 4 at 1:03 PM

0 · Reply

Dogster304 Jul. 31 at 10:38 AM

$ANRO been with this beauty since it was $5 a share

0 · Reply

TripleWitch Jul. 14 at 1:44 AM

$ANRO $PSNL You must mean the one that did the after hours equity offering, no? 🤷‍♂️

0 · Reply

RunnerSignals Jul. 13 at 7:53 PM

red to green $PSNL and $ANRO flipped the script into the close, but one reversal had the cleaner volume signature. traders may be watching the wrong winner

0 · Reply

focafoca99 Jul. 13 at 12:12 PM

$ANRO estimated its cash, cash equivalents and restricted cash at about $244.2 million as of June 30, 2026.

0 · Reply

FaithFilledTrader Jul. 13 at 11:44 AM

$ANRO news

0 · Reply

DiamondHandsJimbo Jul. 10 at 5:59 PM

$ANRO 😝🔥🚀

0 · Reply

DiamondHandsJimbo Jul. 10 at 4:43 PM

$ANRO show me some green LMAO… Entry at $26.14 🤞🚀

0 · Reply

CARTE_BLANCHE_DEVEREAUX Jul. 3 at 6:57 PM

$RILY $SLS $ANRO $OUST $POET The other half of that message from one year ago. What do you guys have planned for the next year? I guess, more importantly... What do WE have planned for next year?

3 · Reply

Ccperk Jun. 26 at 7:48 PM

$ANRO not exactly sure what’s going on here. Partnership or buyout imminent? Who knows

0 · Reply

MrGreenth Jun. 23 at 6:06 PM

$ANRO 30$ next up

0 · Reply

focafoca99 Jun. 15 at 12:32 PM

$ANRO showed significant anhedonia reduction in a Nature Medicine study of pramipexole.

0 · Reply

dumb_money_wins_again Jun. 10 at 2:30 PM

$ANRO bring this back down to 3 dollars lol

0 · Reply

dumb_money_wins_again Jun. 10 at 1:31 PM

$ANRO

0 · Reply

dumb_money_wins_again Jun. 10 at 1:19 PM

$ANRO possible inverted head to poop emoji pattern! ALERT!!

0 · Reply

John1463 Jun. 10 at 11:26 AM

$ANRO: Alto Neuroscience stock is making a strong price recovery with increased bullish momentum and interest. It is climbing out of a stage of being oversold and has made a bullish crossover past the 20-day SMA, with extensive room to go up. It also has strong buy consensus with a price target at $35.13, meaning it still has the room for 66% upside.

0 · Reply

Ccperk Jun. 10 at 11:18 AM

$ANRO I’m not a huge technicals person but drawing the inverted cone method on the one year chart gives me a possible $50 by year end. With upcoming catalyst, new bd mem/bristol myer potential who knows. Will be an interesting Q3/4.

0 · Reply

dumb_money_wins_again Jun. 10 at 5:15 AM

$ANRO I think this tanks 50% lol. its a good time to short folks!

0 · Reply

InvestMRB Jun. 9 at 8:28 PM

$ANRO hmm this can push to 23.

0 · Reply

Stef_DL Jun. 9 at 3:36 PM

$ANRO The market is bleeding red and this does 7%+...

0 · Reply

Market Cap	1.01B
Revenue (ttm)	0.00
Net Income (ttm)	-63.24M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.07

Volume	732,193
Avg Vol	544,968
Day's Range	N/A - N/A
Shares Out	35.09M
Stochastic %K	87%
Beta	1.06
Analysts	Strong Sell
Price Target	$35.33